Cypherpunk Technologies (NASDAQ:CYPH) Raised to “Strong-Buy” at Cantor Fitzgerald

Cypherpunk Technologies (NASDAQ:CYPH) was upgraded by research analysts at Cantor Fitzgerald to a “strong-buy” rating in a research note issued to investors on Wednesday,Zacks.com reports.

Several other equities research analysts have also weighed in on the company. Weiss Ratings lowered Cypherpunk Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, June 25th. Wall Street Zen lowered Cypherpunk Technologies from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th. One analyst has rated the stock with a Strong Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $0.90.

Cypherpunk Technologies Price Performance

NASDAQ CYPH opened at $0.64 on Wednesday. Cypherpunk Technologies has a 12 month low of $0.23 and a 12 month high of $3.70. The company has a market capitalization of $68.57 million, a P/E ratio of -32.19 and a beta of 0.07. The company’s 50 day simple moving average is $0.92 and its 200 day simple moving average is $0.88.

Cypherpunk Technologies (NASDAQ:CYPH) last issued its earnings results on Thursday, May 14th. The company reported ($0.46) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.42).

Institutional Investors Weigh In On Cypherpunk Technologies

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Millennium Management LLC bought a new position in Cypherpunk Technologies during the fourth quarter worth $37,000. LPL Financial LLC bought a new stake in Cypherpunk Technologies in the 4th quarter valued at $38,000. Caitong International Asset Management Co. Ltd acquired a new stake in Cypherpunk Technologies in the 4th quarter worth $44,000. Sequoia Financial Advisors LLC acquired a new stake in Cypherpunk Technologies in the 4th quarter worth $56,000. Finally, HighTower Advisors LLC bought a new position in shares of Cypherpunk Technologies during the 4th quarter worth about $59,000. Institutional investors and hedge funds own 30.46% of the company’s stock.

About Cypherpunk Technologies

Cypherpunk Technologies Inc, previously known as Leap Therapeutics, Inc, is a company developing novel therapies for patients with cancer and implementing a digital asset treasury strategy focused on Zcash. The company’s research platform centers on modulating the tumor microenvironment to enhance anti-tumor immune responses. Cypherpunk’s proprietary pipeline includes DKN-01, a monoclonal antibody designed to neutralize Dickkopf-1 (DKK1), a protein implicated in tumor growth and immune evasion.

DKN-01 is being evaluated both as a monotherapy and in combination with checkpoint inhibitors such as pembrolizumab across multiple solid tumor indications, including gastroesophageal, pancreatic and other advanced malignancies.